Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Study sponsor: Mesoblast, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2014-09-15Actual
Enrollment · participants73Actual
Source updated2026-03-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.